Carisma Therapeutics Inc.
CARMDelisted Dec 15, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001485003
Carisma Therapeutics Inc. was delisted on Dec 15, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 33 institutions reported holding it in 13F filings for Q3 2025, worth $842.6K in total; no superinvestor held it.
13F holders, Q2 2026
Institutional positions in Carisma Therapeutics Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CARM is no longer listed, and 13F filings after Q3 2025 list far fewer holders. See Q3 2025
- Institutional holders
- 1
- −2 vs. Q1 2026
- Shares held
- 785
- −1.47M (−99.9%) vs. Q1 2026
- Total value
- $4
- −$47.9K (−100.0%) vs. Q1 2026
- New holders
- 0
- 0 more added
- Sold out
- 2
- 0 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CARM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $4 |
| Q1 2026 | 3 | $47.9K |
| Q4 2025 | 7 | $67.0K |
| Q3 2025 | 33 | $842.6K |
| Q2 2025 | 36 | $1.56M |
| Q1 2025 | 37 | $1.73M |
| Q4 2024 | 41 | $2.35M |
| Q3 2024 | 37 | $5.11M |
| Q2 2024 | 53 | $9.28M |
| Q1 2024 | 51 | $19.3M |
| Q4 2023 | 50 | $26.4M |
| Q3 2023 | 58 | $39.6M |
| Q2 2023 | 53 | $84.0M |
| Q1 2023 | 37 | $17.3M |
| Q4 2022 | 71 | $19.8M |
| Q3 2022 | 69 | $11.0M |
| Q2 2022 | 74 | $23.1M |
| Q1 2022 | 84 | $26.4M |
| Q4 2021 | 93 | $39.1M |
| Q3 2021 | 103 | $44.5M |
| Q2 2021 | 106 | $305.9M |
| Q1 2021 | 76 | $104.4M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Carisma Therapeutics Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Union Bancaire Privee, UBP SA | 785 | $4 | 0.00% | 00.0% | Unchanged |
| Merck & Co., Inc. | 0 | $0 | 0.00% | −1,473,240−100.0% | Sold out |
| Golden State Equity Partners | 0 | $0 | 0.00% | −200−100.0% | Sold out |